Traders bought shares of Bristol-Myers Squibb Co. (NYSE:BMY) on weakness during trading hours on Thursday. $137.58 million flowed into the stock on the tick-up and $93.56 million flowed out of the stock on the tick-down, for a money net flow of $44.02 million into the stock. Of all companies tracked, Bristol-Myers Squibb had the 9th highest net in-flow for the day. Bristol-Myers Squibb traded down ($1.81) for the day and closed at $74.66

A number of research firms have issued reports on BMY. Vetr raised Bristol-Myers Squibb from a “sell” rating to a “buy” rating and set a $78.73 price target for the company in a research report on Monday. Credit Suisse Group AG reissued an “overweight” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, April 26th. Jefferies Group reissued a “hold” rating and set a $75.00 price target on shares of Bristol-Myers Squibb in a research report on Thursday, May 5th. Berenberg Bank reissued a “buy” rating and set a $80.00 price target on shares of Bristol-Myers Squibb in a research report on Friday, April 22nd. Finally, Deutsche Bank AG reissued a “hold” rating on shares of Bristol-Myers Squibb in a research report on Wednesday, June 15th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $74.65.

The firm has a 50 day moving average price of $73.83 and a 200 day moving average price of $68.13. The company has a market cap of $124.63 billion and a price-to-earnings ratio of 80.19.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.03. The business had revenue of $4.90 billion for the quarter, compared to analyst estimates of $4.60 billion. During the same period in the previous year, the company earned $0.53 earnings per share. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. On average, equities analysts predict that Bristol-Myers Squibb Co. will post $2.60 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 1st. Shareholders of record on Friday, July 1st will be given a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a yield of 2.04%. The ex-dividend date is Wednesday, June 29th.

In other news, EVP Sandra Leung sold 72,544 shares of the firm’s stock in a transaction dated Friday, May 6th. The stock was sold at an average price of $70.39, for a total value of $5,106,372.16. Following the sale, the executive vice president now directly owns 444,507 shares of the company’s stock, valued at $31,288,847.73. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Lamberto Andreotti sold 23,200 shares of the firm’s stock in a transaction dated Friday, July 8th. The shares were sold at an average price of $74.45, for a total value of $1,727,240.00. Following the completion of the sale, the director now directly owns 380,099 shares in the company, valued at $28,298,370.55. The disclosure for this sale can be found here.

Other large investors have modified their holdings of the company. Philadelphia Trust Co. increased its stake in shares of Bristol-Myers Squibb by 0.5% in the fourth quarter. Philadelphia Trust Co. now owns 20,364 shares of the biopharmaceutical company’s stock valued at $1,365,000 after buying an additional 100 shares in the last quarter. Boltwood Capital Management increased its stake in shares of Bristol-Myers Squibb by 1.3% in the fourth quarter. Boltwood Capital Management now owns 15,540 shares of the biopharmaceutical company’s stock valued at $1,069,000 after buying an additional 200 shares in the last quarter. Wellington Shields & Co. LLC increased its stake in shares of Bristol-Myers Squibb by 0.5% in the fourth quarter. Wellington Shields & Co. LLC now owns 52,336 shares of the biopharmaceutical company’s stock valued at $3,600,000 after buying an additional 270 shares in the last quarter. ProVise Management Group LLC increased its stake in shares of Bristol-Myers Squibb by 0.9% in the fourth quarter. ProVise Management Group LLC now owns 31,042 shares of the biopharmaceutical company’s stock valued at $2,135,000 after buying an additional 292 shares in the last quarter. Finally, Pekin Singer Strauss Asset Management IL increased its stake in shares of Bristol-Myers Squibb by 1.0% in the fourth quarter. Pekin Singer Strauss Asset Management IL now owns 33,948 shares of the biopharmaceutical company’s stock valued at $2,335,000 after buying an additional 330 shares in the last quarter.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in BioPharmaceuticals segment. Its pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.